NASDAQ:GMTX Gemini Therapeutics (GMTX) Stock Price, News & Analysis $49.31 -0.64 (-1.28%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$48.31▼$51.1150-Day Range$39.16▼$49.9552-Week Range$1.16▼$3.15Volume202,629 shsAverage Volume189,291 shsMarket Capitalization$2.14 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends Get Gemini Therapeutics alerts: Email Address Ad Angel PublishingWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. About Gemini Therapeutics Stock (NASDAQ:GMTX)Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Read More GMTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMTX Stock News HeadlinesJuly 22, 2024 | businessinsider.comGemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?April 17, 2024 | seekingalpha.comGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysAugust 22, 2024 | Stansberry Research (Ad)The Strange Disappearance of MILLIONS of American JobsA former hedge fund manager who bought Apple at a split-adjusted 35 cents and Amazon at $2.40 (split adjusted) just went issued a major warning.February 26, 2024 | washingtonpost.comGoogle takes down Gemini AI image generator. Here’s what you need to know.February 26, 2024 | nypost.com‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiascoJune 24, 2023 | benzinga.com(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson FistelJune 1, 2023 | barrons.comBronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) InvestigationJanuary 13, 2023 | markets.businessinsider.comThe Winklevoss' Gemini terminates its yield product as dispute between the crypto exchange and DCG escalatesAugust 22, 2024 | Stansberry Research (Ad)The Strange Disappearance of MILLIONS of American JobsA former hedge fund manager who bought Apple at a split-adjusted 35 cents and Amazon at $2.40 (split adjusted) just went issued a major warning.January 1, 2023 | usatoday.comGemini HoroscopeDecember 27, 2022 | finance.yahoo.comDisc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic ProtoporphyriaOctober 31, 2022 | finance.yahoo.comDisc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)September 27, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, PBFX, EVOP, GMTXSeptember 26, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFYSeptember 16, 2022 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZSeptember 6, 2022 | markets.businessinsider.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, DRE, PLD, GMTX, SAFEAugust 25, 2022 | apnews.comThe M&A Class Action Firm Announces the Investigation of Gemini Therapeutics, Inc. – GMTXAugust 24, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds, LOTZ, GMTX, AAWW, and CCXI Shareholders About Its Ongoing InvestigationsSee More Headlines Receive GMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today8/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GMTX CUSIPN/A CIK1816736 Webwww.geminitherapeutics.com Phone415-877-4887FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.78% Return on Assets-35.88% Debt Debt-to-Equity RatioN/A Current Ratio71.49 Quick Ratio71.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book17.06Miscellaneous Outstanding Shares43,328,000Free Float37,739,000Market Cap$2.14 billion OptionableNot Optionable Beta-0.12 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Georges Gemayel C.F.A. (Age 62)Ph.D., Interim Pres & CEO and Exec. Chairperson Comp: $256.73kMr. Brian Piekos (Age 46)Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer Comp: $549.73kMr. Jason Patrick Meyenburg M.B.A. (Age 44)M.D., Advisor Comp: $715.96kMr. Patrick Truesdell (Age 41)VP of Fin. & Controller Key CompetitorsRoivant SciencesNASDAQ:ROIVSummit TherapeuticsNASDAQ:SMMTAscendis Pharma A/SNASDAQ:ASNDIntra-Cellular TherapiesNASDAQ:ITCIRevolution MedicinesNASDAQ:RVMDView All Competitors GMTX Stock Analysis - Frequently Asked Questions How have GMTX shares performed this year? Gemini Therapeutics' stock was trading at $57.76 on January 1st, 2024. Since then, GMTX stock has decreased by 14.6% and is now trading at $49.31. View the best growth stocks for 2024 here. How were Gemini Therapeutics' earnings last quarter? Gemini Therapeutics, Inc. (NASDAQ:GMTX) released its earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.04. How do I buy shares of Gemini Therapeutics? Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GMTX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact ...Crypto 101 Media | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
